- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03453567
Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice (IRIS AVR)
Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jung-hee Ham, RN
- Phone Number: +82230104728
- Email: cvcrc5@amc.seoul.kr
Study Contact Backup
- Name: Seung-jung Park, MD
- Email: sjpark@amc.seoul.kr
Study Locations
-
-
-
Bucheon, Korea, Republic of
- Recruiting
- Sejong Hospital
-
Contact:
- Hee-moon Lee, MD
- Email: rhythmists@gmail.com
-
Principal Investigator:
- Hee-moon Lee, MD
-
Seoul, Korea, Republic of
- Recruiting
- Asan Medical Center
-
Contact:
- Seung-jung Park, MD
- Email: sjpark@amc.seoul.kr
-
Principal Investigator:
- Seung-jung Park, MD
-
Yangsan, Korea, Republic of
- Recruiting
- Pusan National University Yangsan Hospital
-
Contact:
- Hyoung-gon Je, MD
- Email: jehg7332@gmail.com
-
Principal Investigator:
- Hyoung-gon Je, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 19 and more
- Patient with aortic valve replacement
Exclusion Criteria:
- Combined with mitral stenosis requiring surgery or aorta stenosis
- Acute bacterial endocarditis within 1 month of valve replacement
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
TAVR
Transcatheter Aortic Valve Replacement
|
Aortic valve replacement
|
Sutureless AVR
Sutureless Aortic Valve Replacement
|
Aortic valve replacement
|
Conventional AVR
Conventional Aortic Valve Replacement
|
Aortic valve replacement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All-cause death
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular mortality
Time Frame: 5 years
|
A. Death due to proximate cardiac cause B. Death caused by noncoronary vascular condition C. All procedure-related/surgery-related death D. All valve-related death E. Sudden or unwitnessed death F. Death of unknown cause Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Myocardial infarction
Time Frame: 5 years
|
Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
All stroke and transient ischemic attack
Time Frame: 5 years
|
Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Bleeding
Time Frame: 5 years
|
Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Access site complication
Time Frame: 5 years
|
Operation site complication Vascular access site and access-related complication Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Acute kidney injury
Time Frame: 5 years
|
Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Permanent pacemaker insertion
Time Frame: 5 years
|
Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
TAVR-related complication
Time Frame: 5 years
|
A. Conversion to open surgery B. Coronary obstruction C. Mitral valve apparatus damage or dysfunction D. Cardiac tamponade E. Endocarditis F. Valve thrombosis G. Valve malpositioning H. TAV-in-TAV deployment Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Prosthetic valve dysfunction
Time Frame: 5 years
|
A. Prosthetic aortic valve stenosis B. Prosthesis-patient mismatch C. Prosthetic aortic valve regurgitation Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Composite event
Time Frame: 5 years
|
A. Device success B. Early safety (30 days)
Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
Structural valve deterioration
Time Frame: 5 years
|
Either Discharge or 30-day, at the earliest time point 1-,6-, and 12-months, and 3-,5-years |
5 years
|
NYHA class
Time Frame: 30 days and 1 year
|
New York Heart Association (NYHA) Functional Classification
|
30 days and 1 year
|
The change of valve area
Time Frame: 30 days and 1 year
|
Aortic valve area measured by echocardiography (mm2)
|
30 days and 1 year
|
New onset atrial fibrillation
Time Frame: 30 days and 1 year
|
30 days and 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Suk-Jung Choo, MD, Asan Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMCCV2018-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingHeart Failure | Aortic Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral StenosisUnited States, Canada, Poland
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
BC Centre for Improved Cardiovascular HealthEdwards LifesciencesUnknownTranscatheter Aortic Valve Implantation | Severe Aortic StenosisCanada
Clinical Trials on Valve Replacement
-
Assiut UniversityUnknownMitral Valve DiseaseEgypt
-
Federal University of BahiaCompletedMitral Insufficiency | Mitral StenosisBrazil
-
OptimapharmEdwards LifesciencesActive, not recruitingAortic Valve Stenosis | Heart Valve DiseasesUnited Kingdom, Italy, Germany, France, Austria, Switzerland, Finland, Czechia, Belgium, Netherlands, Cyprus, Ireland
-
Karolinska University HospitalKarolinska InstitutetCompletedAortic Valve Stenosis | Heart Valve DiseasesSweden
-
Edwards LifesciencesActive, not recruitingCardiovascular Diseases | Heart Valve Diseases | Tricuspid Valve RegurgitationUnited States, Canada, France, Switzerland
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Assistance Publique - Hôpitaux de ParisUnknownAortic Valve Stenosis | Aortic Valve SurgeryFrance
-
St. Antonius HospitalCompletedQuality of Life | Aortic Valve Stenosis | Limited Access Aortic Valve ReplacementNetherlands
-
Medtronic Bakken Research CenterCompletedAortic Heart Valve DiseasesBelgium, Netherlands, Italy, United Kingdom
-
Medtronic CardiovascularActive, not recruitingAortic Valve StenosisUnited States, Australia, New Zealand, Canada, Netherlands, France, Japan